Literature DB >> 15726304

[Antitumour vaccination in patients with ENT tumours. Successful track record].

G Dyckhoff1, C Herold-Mende.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15726304     DOI： 10.1007/s00106-005-1226-1

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


× No keyword cloud information.
  10 in total

1.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Authors:  Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

Review 2.  Immunization with virus-modified tumor cells.

Authors:  V Schirrmacher; T Ahlert; T Pröbstle; H H Steiner; C Herold-Mende; R Gerhards; E Hagmüller; H H Steiner
Journal:  Semin Oncol       Date:  1998-12       Impact factor: 4.929

3.  Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer.

Authors:  M Tisch; F Heimlich; V Daniel; G Opelz; H Maier
Journal:  Otolaryngol Head Neck Surg       Date:  1998-10       Impact factor: 3.497

4.  Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.

Authors:  H Qin; J Valentino; S Manna; P K Tripathi; M Bhattacharya-Chatterjee; K A Foon; B W O'Malley; S K Chatterjee
Journal:  Mol Ther       Date:  2001-12       Impact factor: 11.454

Review 5.  Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Authors:  M R Young; D M Lathers
Journal:  Int J Immunopharmacol       Date:  1999-04

6.  Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis.

Authors:  J H Heimdal; H J Aarstad; B Klementsen; J Olofsson
Journal:  Acta Otolaryngol       Date:  1999-03       Impact factor: 1.494

7.  Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.

Authors:  Jochen Karcher; Gerhard Dyckhoff; Philipp Beckhove; Christoph Reisser; Michael Brysch; Yvonne Ziouta; Burkhard H Helmke; Hagen Weidauer; Volker Schirrmacher; Christel Herold-Mende
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma.

Authors:  G R Thomas; Z Chen; I Enamorado; C Bancroft; C Van Waes
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

9.  Postoperative active-specific immunotherapy of lymph node micrometastasis in a guinea pig tumor model.

Authors:  H Bier; G Armonat; J Bier; V Schirrmacher; U Ganzer
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1989       Impact factor: 1.538

10.  Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes.

Authors:  Karl Götte; Dirk Usener; Frank Riedel; Karl Hörmann; Dirk Schadendorf; Stefan Eichmüller
Journal:  Acta Otolaryngol       Date:  2002-07       Impact factor: 1.494
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.